News & Updates

Lipid levels a glaucoma risk?
Lipid levels a glaucoma risk?
05 Apr 2022 byAudrey Abella

Glaucoma appears to be associated with high total cholesterol and low high-density lipoprotein (HDL) levels, according to a systematic review and meta-analysis of observational studies.

Lipid levels a glaucoma risk?
05 Apr 2022
Resistance exercise could improve sleep duration, efficiency
Resistance exercise could improve sleep duration, efficiency
04 Apr 2022 byRoshini Claire Anthony

Individuals at elevated cardiovascular disease risk (overweight/obese, increased blood pressure levels) may improve the duration and efficiency of their sleep through regular resistance exercise regimens, according to a study presented at the EPI Lifestyle Scientific Sessions 2022.

Resistance exercise could improve sleep duration, efficiency
04 Apr 2022
ED patients who do not respond to PDE5I may benefit from topical alprostadil–PDE5i combo
ED patients who do not respond to PDE5I may benefit from topical alprostadil–PDE5i combo
04 Apr 2022 byJairia Dela Cruz

For men with erectile dysfunction (ED) who show a lack of response to oral phosphodiesterase type 5 inhibitors (PDE5Is), combination therapy with topical alprostadil plus PDE5Is seems favourable, producing greater improvements in sexual function without compromising safety compared with topical alprostadil alone, as shown in a study.

ED patients who do not respond to PDE5I may benefit from topical alprostadil–PDE5i combo
04 Apr 2022
FVC decline predicts death in patients with progressive fibrosing ILD
FVC decline predicts death in patients with progressive fibrosing ILD
04 Apr 2022 byStephen Padilla

Patients with idiopathic pulmonary fibrosis (IPF) exhibit a similar course of lung injury with those having other forms of progressive fibrosing interstitial lung disease (ILD), reveals a study, which also shows the association of forced vital capacity (FVC) decline with short-term mortality in this population.

FVC decline predicts death in patients with progressive fibrosing ILD
04 Apr 2022
Subclinical hyperthyroidism not a risk factor for MACE in PCI patients
Subclinical hyperthyroidism not a risk factor for MACE in PCI patients
04 Apr 2022

Subclinical hyperthyroidism (SHyper) does not independently correlate with major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), results of a study have shown.

Subclinical hyperthyroidism not a risk factor for MACE in PCI patients
04 Apr 2022